METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST

Abstract

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

Description

[0001]This application claims the benefit of priority of U.S. Provisional Patent Application No. 61 / 027,741, filed Feb. 11, 2008, and European Patent Application No. 08250703.9, filed Feb. 29, 2008, the entire contents of both of which are incorporated by reference.[0002]Prostate cancer is a leading cause of morbidity and mortality for men in the industrialized world. The American Cancer Society estimates that during 2007 about 218,890 new cases of prostate cancer will have been diagnosed in the United States alone. Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. However, while about 1 man in 6 will be diagnosed with prostate cancer during his lifetime, only 1 man in 35 will actually die of it. The American Cancer Society estimates that 27,050 men in the United States will die of prostate cancer in 2007. Prostate cancer accounts for about 9% of cancer-related deaths in men.[0003]While prostate cancer incidence rates rose dramatic...

AI Technical Summary

Benefits of technology

The patent describes a method of treating prostate cancer with a low dose of a drug called degarelix, which can quickly and safely lower testosterone levels without causing a spike in testosterone levels or side effects associated with other drugs used for this purpose. The method involves giving a low initial dose of degarelix and then a maintenance dose every 28 days. This treatment approach reduces the risk of side effects and is particularly useful for patients who are at risk for cardiovascular disease or have locally advanced prostate cancer. It also reduces the likelihood of developing non-infective cystitis, urinary tract infections, erectile dysfunction, and muscle and connective tissue disorders. Overall, this method provides a safer and more effective way to treat prostate cancer.

Problems solved by technology

Additionally, each successive administration of the agonist can cause an additional small LH surge (known as the “acute-on chronic” phenomenon) that can further worsen the condition.

The use of antiandrogens, however, is associated with serious hepatic and gastrointestinal side effects.

This histamine-releasing activity represents a serious obstacle to the clinical use of such antagonists because histamine release results in adverse side effects such as edema and itching.

While the use of both GnRH agonist and antagonists in androgen deprivation therapy to treat prostate cancer has yielded promising results, there are concerns about the relative safety of the available drugs.

For example, the GnRH abarelix was found to carry a risk of serious allergic reactions, including anaphylaxis with hypotension and syncope, and was also found to lose efficacy over the course of treatment in some cases.

Indeed, Abarelix™ (Plenaxis™ in the U.S.) was eventually approved, but only for patients with advanced prostate cancer, and was eventually withdrawn from the market in 2005 for commercial reasons apparently related to these problems.

Furthermore, while prostate cancer-specific mortality has been decreasing, there has been little overall effect on mortality in this group, suggesting the possibility of an increased risk of death from nonprostate cancer related causes.

In particular, it has been suggested that certain androgen deprivation therapies could adversely affect cardiovascular health (see Yannucci et al.

There is a significant risk of the thrombus embolizing and traveling to the lungs causing a pulmonary embolism.

Administration of degarelix by subcutaneous or intramuscular injection works well, but daily injections are generally not acceptable and so a depot formulation of degarelix may be utilized as describe in further detail in WO 03 / 006049 and U.S. Pub. Nos. 20050245455 and 20040038903.

If the formulation is too dilute then no depot is formed and the long duration of action is lost, regardless of the amount of drug substance given.

The most commonly observed adverse reactions during degarelix therapy were due to the expected physiological effects of testosterone suppression, mainly hot flushes and increased weight, and injection site related adverse events, mainly injection site pain and injection site erythema.

In addition, habitual smoking has been shown to be associated with an increased risk for cardiovascular disease.

Images